Effects of long-term treatment with Serenoa repens (Permixon®) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia

Prostate

Volumn 37, Issue 2, 1998, Pages 77-83

  Di Silverio, F ^a   Monti, S ^a   Sciarra, A ^a   Varasano, P A ^a   Martini, C ^a   Lanzara, S ^a   D'Eramo, G ^a   Di Nicola, S ^a   Toscano, V ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

BPH; Dihydrotestosterone; Growth factors; Periurethral zone; Serenoa repens (Permixon ); Testosterone

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; EPIDERMAL GROWTH FACTOR; STEROID 5ALPHA REDUCTASE; TESTOSTERONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LONG TERM CARE; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RADIOIMMUNOASSAY; SABAL; URINARY TRACT OBSTRUCTION;

AGED; ANDROGEN ANTAGONISTS; CHOLESTENONE 5 ALPHA-REDUCTASE; DIHYDROTESTOSTERONE; EPIDERMAL GROWTH FACTOR; HUMANS; MALE; MIDDLE AGED; OXIDOREDUCTASES; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; SERENOA; TESTOSTERONE;

EID: 0031706319     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19981001)37:2<77::AID-PROS3>3.0.CO;2-I     Document Type: Article

References (42)

1. Briley M, Carilla E, Roger A, Couzinier JA: A new treatment of prostatic hyperplasia. Permixon has antiandrogen effects at two complementary levels. New Trends Androl Sci 1985;1:24-26.
2. Raynaud JP: Permixon®: An overview of its pharmacological activities as regards medical treatment of benign prostatic hypertrophy (BPH). In Dimopoulos CA, Di Silverio F (eds): "BPH: From Molecular Biology to Patient Relief," Bologna: Monduzzi Editore, 1996:57-69.
3. Prosker GL, Brogden RN: Serenoa repens (Permixon®). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996;9:379-395.
4. Carilla E, Briley M, Fauran F, Sultan C, Duvilliers C: Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem 1984;20:521-523.
5. Sultan C, Terraza A, Devillier C, Carilla E, Briley M, Loire C, Descomps B: Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblasts. J Steroid Biochem 1984;20:515-519.
6. Siiteri PK, Wilson JD: Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest 1970;49:1737-1745.
7. Jenkins EP, Andersson S, Imperato-McGinley J, Wilson JD, Russell DW: Genetic and pharmacological evidence for more than one human steroid 5 alpha reductase. J Clin Invest 1992;89:293-300.
8. Bonnet P, Reiter E, Bruyninx M, Sente B, Dombrowicz D, de Leval J, Closset J, Hennen G: Benign prostatic hyperplasia and normal prostate aging: Differences in type I and II 5-alpha-reductase and steroid hormone receptor messenger ribonucleic acid (mRNA) levels, but not in insulin like growth factor mRNA levels. J Clin Endocrinol Metab 1993;77:1203-1208.
9. Iehlé C, Raynaud JP, Martin PM: Steroid 5 alpha reductase type 1 is expressed in the human pathological prostate [abstract]. J Urol [Suppl] 1996;155:808.
10. Ross M, Chapman K, Habib FK: The expression of type 1 and type 2 5-alpha reductase mRNA in BPH and prostate cancer and in short term primary cultures of prostate epithelial and stromal cells. In British Prostate Group (eds): "Future Perspectives in Prostatic Disease," University of York, 1996:22-32.
11. Levine AC, Wang JP, Ren M, Eliashvili E, Russell DW, Kirschenbaum A: Immunohistochemical localization of steroid 5 alpha reductase 2 in the human male fetal reproductive tract and adult prostate. J Clin Endocrinol Metab 1996;81:384-389.
12. Silver RJ, Wiley EL, Davis DL, Thigpen AE, Russell DW, McConnell JD: Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease. J Urol 1994;152:433-437.
13. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW: Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 1993;92:903-910.
14. Délos S, Iehlé C, Martin PM, Raynaud JP: Inhibition of the activity of "basic" 5 alpha reductase (type 1) detected in DU 145 cells and expressed in insect cells. J Steroid Biochem Mol Biol 1994;48:347-352.
15. Iehlé C, Délos S, Guirou O, Tate R, Raynaud JP, Martin PM: Human prostatic steroid 5 alpha reductase isoforms - A comparative study of selective inhibitors. J Steroid Biochem Mol Biol 1995;54:273-279.
16. Délos S, Carsol JL, Ghazarossian E, Raynaud JP, Martin PM: Testosterone metabolism in primary cultures of human prostate epithelial cells and fibroblasts. J Steroid Biochem Mol Biol 1995; 55:375-383.
17. Bayne CW, Grant ES, Chapman K, Habib FK: Characterization of a new co-culture model for BPH which expresses 5 alpha reductase type 1 and type 2: Effects of Permixon® on DHT formation [abstract]. J Urol [Suppl] 1997;157:194.
18. Schröder FH: 5 alpha-reductase inhibitors and prostatic disease. Clin Endocrinol (Oxf) 1994;41:139-147.
19. Paubert-Braquet M, Raynaud JP, Braquet PG: Permixon® [lipid sterolic extract of Serenoa repens (LSESr)] and some of its components inhibit bFGF-and EGF-induced proliferation of human prostate organotypic cell lines. J Urol [Suppl] 1997;157:138.
20. McKeehan WL, Adams PS, Rosser MP: Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum-free, primary cell culture. Cancer Res 1984;44:1998-2010.
21. Sciarra F, Monti S, Adamo MV, Palma E, Toscano V, d'Eramo G, Di Silverio F: Regional distribution of epidermal growth factor, testosterone and dihydrotestosterone in benign prostatic hyperplasia tissue. Urol Res 1995;23:387-390.
22. Lubrano C, Petrangeli E, Catizone A, Santonati A, Concolino G, Rombolà N, Frati L, Di Silverio F, Sciarra F: Epidermal growth factor binding and steroid receptor content in human benign prostatic hyperplasia. J Steroid Biochem 1989;34:499-504.
23. Toscano V, Petrangeli E, Adamo MV, Foli S, Caiola S, Sciarra F: Simultaneous determination of 5 alpha reduced metabolites of testosterone in human plasma. J Steroid Biochem 1981;14:574-578.
24. Petrangeli E, Sciarra F, Di Silverio F, Toscano V, Lubrano C, Conti C, Concolino G: Effects of two different medical treatments on dihydrotestosterone content and androgen receptors in human benign prostatic hyperplasia. J Steroid Biochem 1988; 30:395-399.
25. Lubrano C, Sciarra F, Spera G, Petrangeli E, Toscano V, Rombolà N, Palleschi F, Palma E, Di Silverio F: Immunoreactive EGF in human benign prostatic hyperplasia: Relationships with androgen and estrogen receptors. J Steroid Biochem Mol Biol 1992; 41:683-687.
26. Monti S, Sciarra F, Adamo MV, Toscano V, Trotta MC, Martini C, Lanzara S, Di Silverio F: Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by treatment with finasteride or flutamide. J Androl 1997;18:488-494.
27. Geller J: Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab 1990;71:1552-1555.
28. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E: Finasteride, an inhibitor of 5 alpha reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992;74:505-508.
29. Norman RW, Coakes KE, Wright AS, Rittmaster RS: Androgen metabolism in men receiving finasteride before prostatectomy. J Urol 1993;150:1736-1739.
30. Rittmaster RS, Norman RW, Thomas LN, Rowden G: Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab 1996;81:814-819.
31. Liang T, Liao S: Inhibition of steroid 5 alpha reductase by specific aliphatic unsaturated fatty acids. Biochem J 1992;285:557-562.
32. Rhodes L, Primka RL, Berman C, Vergult G, Gabriel M, Malice MP, Gibelin B: Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Prostate 1993;22: 43-51.
33. Toscano V, Horton R: Circulating dihydrotestosterone may not reflect peripheral formation. J Clin Invest 1987;79:1653-1658.
34. Oesterling JE: LHRH agonist. A nonsurgical treatment for benign prostatic hyperplasia. J Androl 1991;12:381-388.
35. Prahalada SR, Keenan KP, Hertzog PR, Gordon LR, Peter CP, Soper KA, van Zwieten MJ, Bokelman DL: Qualitative and quantitative evaluation of prostatic histomorphology in rats following chronic treatment with finasteride, a 5-alpha reductase inhibitor. Urology 1994;43:680-685.
36. Monti S, Adamo MV, Trotta MC, Toscano V, Palma E, Martini C, Sciarra F: Regional distribution of cytosolic (ARc) and nuclear (ARn) androgen receptors, testosterone (T) and dihydrotestosterone (DHT) in tissue samples of human benign prostatic hyperplasia (BPH) [abstract]. Int J Androl [Suppl] 1996;19:20.
37. Pierrepoint CG, Davies P, Millington D, John B: Evidence that the deferential vein acts as a local transport system for androgen in the rat and the dog. J Reprod Fertil 1975,43:293-303.
38. Boulanger P, Desaulniers M, Bleau G, Roberts KD, Chapdelaine A: Sex steroid concentrations in plasma from the canine deferential vein. J Endocrinol 1983;96:223-228.
39. Ravenna L, Di Silverio F, Russo MA, Salvatori L, Morgante E, Morrone S, Cardillo MR, Russo A, Frati L, Gulino A, Petrangeli E: Effects of the lipidosterolic extract of Serenoa repens (Permixon®) on human prostatic cell lines. Prostate 1996;29:219-230.
40. Descotes JL, Rambeaud JJ, Deschaseaux P, Faure G: Placebo controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 1995;9:291-297.
41. Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, Calais da Silva F, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marancak J, Perier A, Perrin P: Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients. Prostate 1996;29:231-240.
42. Paubert-Braquet M, Richardson FO, Servent-Saez N, Gordon WC, Monge MC, Bazan NG, Authié D, Braquet P: Effect of Serenoa repens extract (Permixon®) on estradiol/testosterone-induced experimental prostate enlargement in the rat. Pharmacol Res 1996;34:171-179.